A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Year: 2025
Type: article
Abstract: • High dose melphalan in multiple myeloma is associated with significant GI toxicity. • Effective prophylactic options are needed to reduce toxicity and improve outcomes. • Uproleselan, an E-selectin antagonist, may reduce GI toxicity from melphalan. • Further studies are needed to test this hypothesis and optimize dosing strategies.
Institution: Washington University in St. Louis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Award: Cancer Center Support Grant
OpenAlex ID: W4416058519